CLINICAL_TRIALS
trial_result
· 2026-04-08
Clinical Trial Update: A Study of EXG102-031 in Patients With wAMD (Everest) [Phase 1]
Summary
Phase 1 study of EXG102-031 in neovascular (wet) age-related macular degeneration has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Exegenesis Bio | Conditions: Neovascular (Wet) Age-related Macular Degeneration (nAMD) | Phase 1 | Status: COMPLETED